Pneumococcal Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Conjugate Vaccines, Polysaccharide Vaccines), By Indication (Bronchitis, Meningitis, Pneumonia, Sepsis), By Product (Pneumovax23, Prevnar 13, Synflorix), By Distribution (Government Authorities, Non-Governmental Organizations), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 9.71 Billion
CAGR (2026-2031)	6.26%
Fastest Growing Segment	Conjugate Vaccines
Largest Market	North America
Market Size (2031)	USD 13.98 Billion

Market Overview

The Global Pneumococcal Vaccine Market will grow from USD 9.71 Billion in 2025 to USD 13.98 Billion by 2031 at a 6.26% CAGR. The Global Pneumococcal Vaccine Market comprises biological preparations such as conjugate and polysaccharide vaccines designed to elicit an immune response against the Streptococcus pneumoniae bacterium. The market is primarily supported by the rising incidence of pneumococcal diseases like pneumonia coupled with the expansion of national immunization programs. Furthermore, the increasing geriatric population susceptible to respiratory infections continues to drive the demand for preventative measures across both developed and emerging economies.

However, the sector faces a significant challenge due to the high costs of manufacturing and procurement which limits accessibility in developing regions. This financial barrier often hinders the full implementation of immunization schedules. According to the World Health Organization, in 2024, the pneumococcal vaccine had been introduced in 163 Member States achieving a global third dose coverage rate of 67 percent. Such disparities in reach highlight the persistent difficulty of ensuring equitable supply and funding to sustain comprehensive market growth.

Key Market Drivers

The Expansion of Government-Led National Immunization Programs serves as a primary catalyst for the Global Pneumococcal Vaccine Market, particularly in low- and middle-income regions where accessibility has historically been limited. International alliances are increasingly collaborating with local governments to share the financial burden of vaccine introduction, thereby creating a sustainable procurement model. This cost-sharing mechanism not only stabilizes demand for manufacturers but also encourages the integration of pneumococcal conjugates into routine schedules. According to Gavi, the Vaccine Alliance, September 2025, in the 'Annual Progress Report 2024', country co-financing of Gavi-supported vaccines reached a record US$ 255 million in 2024, demonstrating a significant increase in domestic fiscal commitment towards immunization sustainability.

Concurrently, the Growing Geriatric Population Susceptible to Pneumococcal Infections is intensifying the demand for high-valency prophylactic measures in developed and developing nations alike. As immune function naturally declines with age, the elderly demographic faces a disproportionately higher risk of severe invasive pneumococcal disease (IPD), necessitating targeted adult vaccination strategies. This vulnerability is evidenced by surveillance data; according to the Institute of Environmental Science and Research, May 2025, in the 'Invasive Pneumococcal Disease Annual Report 2024', adults aged 65 years and older recorded the highest incidence of invasive pneumococcal disease at 34.2 per 100,000 population. Major pharmaceutical entities continue to leverage this demand to maintain substantial commercial operations. For instance, according to Pfizer, November 2025, in the 'Third-Quarter 2025 Results' report, the company reported total revenues of $16.7 billion, reflecting the robust commercial performance of its diverse portfolio which includes the leading Prevnar vaccine family.

Download Free Sample Report

Key Market Challenges

The high cost associated with manufacturing and procuring pneumococcal vaccines presents a formidable barrier to market expansion, particularly within low- and middle-income nations. The complex biological processes required to produce conjugate vaccines necessitate significant capital investment, resulting in elevated pricing structures that effectively strain national health budgets. Consequently, many developing regions struggle to allocate sufficient funds for autonomous procurement, often relying on external subsidies to maintain immunization schedules. When financial constraints force governments to delay purchases or limit rollout, the uptake of these essential vaccines stalls, directly impeding the volume growth of the global market in these high-demand geographies.

This financial strain is quantifiable through the increasing monetary obligations placed on developing economies. According to Gavi, the Vaccine Alliance, in 2024, lower-income countries collectively contributed nearly US$ 255 million towards their own vaccination programs through co-financing arrangements, representing a 19 percent increase from the previous year. This escalating cost burden underscores the persistent difficulty resource-constrained nations face in sustaining widespread immunization coverage, thereby limiting the market's potential to reach saturation without continuous external funding.

Key Market Trends

The Accelerated Shift Toward Ultra-High Valency Conjugate Vaccines is fundamentally reshaping the competitive landscape as manufacturers race to broaden serotype coverage beyond the standard 20-valent formulations. This trend is driven by the critical need to mitigate the "replacement phenomenon," where non-vaccine serotypes become pathogenic, prompting the rapid commercialization of next-generation pneumococcal conjugates (PCVs) designed specifically for adult populations. The market’s enthusiastic reception of these broader-spectrum options is evident in the immediate financial performance of recently approved products. According to Merck & Co., Inc., October 2025, in the 'Third-Quarter 2025 Sales and Earnings' report, the company recorded sales of US$ 244 million for its newly launched 21-valent vaccine, Capvaxive, driven by strong demand from retail pharmacies and seasonal inventory stocking. This uptake underscores the high clinical value placed on expanded valency for effectively reducing invasive pneumococcal disease burden.

Simultaneously, the Emergence of Cost-Effective Indigenous Vaccine Manufacturing in Developing Regions is challenging the historical dominance of established Western multinationals by creating a sustainable, low-cost supply chain. Local biotechnology firms, particularly in India, are aggressively expanding production capacities to meet the demands of the Global South, thereby reducing reliance on external subsidies and international procurement delays. This strategic expansion is supported by substantial capital allocation toward infrastructure and research to ensure autonomous supply security. According to Biological E. Limited, December 2025, in the 'BE Signs MoU with Telangana Govt.' press release, the company committed a total cumulative investment of ₹4,000 crore to establish state-of-the-art vaccine research and manufacturing facilities. Such investments are pivotal in stabilizing the global supply of affordable pneumococcal vaccines and ensuring equitable access across low- and middle-income nations.

Segmental Insights

The conjugate vaccines segment is distinguishing itself as the fastest-growing category within the global pneumococcal vaccine market. This expansion is primarily driven by the superior immunogenicity of these vaccines, which offer longer-lasting protection compared to polysaccharide alternatives. Regulatory endorsements from agencies such as the U.S. FDA for expanded usage in both pediatric and adult populations have further accelerated adoption. Additionally, the widespread inclusion of these formulations in national immunization programs globally ensures sustained demand, as healthcare systems prioritize vaccines that provide robust immune memory and effectively reduce disease transmission across vulnerable demographics.

Regional Insights

North America maintains a dominant position in the global pneumococcal vaccine market, primarily driven by established healthcare infrastructure and comprehensive immunization coverage. The region benefits from proactive government recommendations, such as those from the U.S. Centers for Disease Control and Prevention, which advocate for routine vaccination across vulnerable demographic groups. Furthermore, the presence of major pharmaceutical manufacturers and favorable reimbursement policies accelerates the adoption of novel formulations. The U.S. Food and Drug Administration also plays a critical role by facilitating the timely approval of new vaccines, thereby sustaining high market penetration throughout the region.

Recent Developments

• In December 2024, Sanofi and SK bioscience expanded their collaboration to develop and commercialize next-generation pneumococcal conjugate vaccines. As part of this agreement, the partners initiated a global Phase 3 clinical program for their 21-valent vaccine candidate, designed to protect infants and toddlers. The updated deal included an upfront payment of €50 million from Sanofi to SK bioscience, with provisions for future development and commercial milestones. The Executive Vice President of Vaccines at Sanofi emphasized that the partnership aimed to address unmet public health needs by leveraging the strengths of both companies. The vaccine candidate became the first with more than 20 serotypes to enter late-stage clinical trials for the pediatric population.
• In September 2024, Vaxcyte, Inc. reported positive topline results from a Phase 1/2 clinical study evaluating VAX-31, its 31-valent pneumococcal conjugate vaccine candidate. The study assessed the safety, tolerability, and immunogenicity of the vaccine in adults aged 50 and older. The results demonstrated that the vaccine was well-tolerated and elicited robust immune responses for all 31 serotypes included in the formulation. The company’s Executive Vice President noted that the data met or exceeded regulatory immunogenicity criteria, showing superiority for several serotypes compared to the standard-of-care 20-valent vaccine. Based on these findings, the company announced plans to advance the candidate into a pivotal Phase 3 program for adults in mid-2025.
• In June 2024, Merck announced that the U.S. Food and Drug Administration approved CAPVAXIVE, a 21-valent pneumococcal conjugate vaccine, for use in adults. This specific formulation was designed to protect against 21 serotypes of Streptococcus pneumoniae that are responsible for the majority of invasive pneumococcal disease in adults aged 50 and older. The approval was supported by data from the Phase 3 STRIDE-3 trial, which compared the immunogenicity of the new vaccine to an existing 20-valent comparator. The President of Merck Research Laboratories highlighted that this approval represented a population-specific strategy, providing a new option tailored to protect against the specific strains causing significant disease burden in adult populations.
• In March 2024, Pfizer Inc. received marketing authorization from the European Commission for its 20-valent pneumococcal conjugate vaccine, marketed as PREVENAR 20, for the protection of infants and children. This approval covered active immunization against invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae in individuals from six weeks to less than 18 years of age. The authorization was valid across all 27 European Union member states. The Chief International Commercial Officer at Pfizer stated that this development offered the broadest serotype coverage for a pediatric pneumococcal conjugate vaccine in Europe, addressing a significant public health need by targeting serotypes responsible for the majority of pneumococcal disease cases in the region.

Key Market Players

• GSK PLC
• Pfizer Inc
• Merck KGaA
• Serum Institute of India Pvt Ltd
• CSL Ltd
• Sanofi SA
• Walvax Biotechnology Co., Ltd
• Beijing Minhai Biotechnology Limited Company
• AstraZeneca PLC
• BioNTech

By Type	By Indication	By Product	By Distribution	By Region
Conjugate Vaccines Polysaccharide Vaccines	Bronchitis Meningitis Pneumonia Sepsis	Pneumovax23 Prevnar 13 Synflorix	Government Authorities Non-Governmental Organizations	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Pneumococcal Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pneumococcal Vaccine Market, By Type:

• Conjugate Vaccines
• Polysaccharide Vaccines

• Pneumococcal Vaccine Market, By Indication:

• Bronchitis
• Meningitis
• Pneumonia
• Sepsis

• Pneumococcal Vaccine Market, By Product:

• Pneumovax23
• Prevnar 13
• Synflorix

• Pneumococcal Vaccine Market, By Distribution:

• Government Authorities
• Non-Governmental Organizations

• Pneumococcal Vaccine Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE